retatrutide phase 3 trial results Weight Loss Results:Trial Data and FDA Status New GLP-3 drug significantly slashes

Melanotan II may support increased melanin production, which can gradually deepen skin tone without relying on direct UV exposure

86.4% of patients lost at least 5% of their body weight 69.1% lost at least 10% 50.5% (more than half) lost at least 15% after 68 weeks of treatment with semaglutide On average, patients in the semaglutide group lost 15.3 kg of their weight 12.7 kg more than the weight loss achieved with the placebo (2.6 kg)

Ngondi 2005)

Cell (2004) 118(2):22941.10.1016/j.cell.2004.07.002 146 WorthingtonJJSamuelsonLCGrencisRKMcLaughlinJT

29 In a study involving 1,306 overweight or obese individuals receiving 2.4 mg of semaglutide, approximately 6% and 12% weight loss was observed at 12 and 28 weeks, respectively, and total fat mass decreased by approximately 20% after 56 weeks of treatment